575 related articles for article (PubMed ID: 8808724)
21. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
Park JO; Rha SY; Yoo NC; Kim JH; Roh JK; Min JS; Kim BS; Chung HC
Am J Clin Oncol; 1997 Dec; 20(6):569-72. PubMed ID: 9391542
[TBL] [Abstract][Full Text] [Related]
23. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
25. [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
Ishioka S; Sagae S; Saito T; Kiya T; Sugimura M; Akutagawa N; Umemura K; Ito E; Kudo R
Gan To Kagaku Ryoho; 2000 Apr; 27(4):593-8. PubMed ID: 10791002
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
[TBL] [Abstract][Full Text] [Related]
28. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
29. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
Kalaycio M; Mendez Z; Pohlman B; Overmoyer B; Boparai N; Jones E; Bolwell B
J Cancer Res Clin Oncol; 1998; 124(5):265-9. PubMed ID: 9645457
[TBL] [Abstract][Full Text] [Related]
30. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
Dempsey CL; Coop AJ; Shillington A; Farley PA; Eberhardt DR; O'Briant S
Am J Health Syst Pharm; 2004 Apr; 61(8):781-6. PubMed ID: 15127961
[TBL] [Abstract][Full Text] [Related]
31. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
[TBL] [Abstract][Full Text] [Related]
32. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
[TBL] [Abstract][Full Text] [Related]
33. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
Simpson K; Spencer CM; McClellan KJ
Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
[TBL] [Abstract][Full Text] [Related]
34. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
[TBL] [Abstract][Full Text] [Related]
35. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
36. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
[TBL] [Abstract][Full Text] [Related]
37. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Morrow GR; Hickok JT; Rosenthal SN
Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
[TBL] [Abstract][Full Text] [Related]
38. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
39. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Poon RT; Chow LW
Br J Cancer; 1998 May; 77(10):1683-5. PubMed ID: 9635849
[TBL] [Abstract][Full Text] [Related]
40. An audit of antiemetic use with CMF chemotherapy.
Brown RS; Brown TK; Hoare D; Gaze MN
Clin Oncol (R Coll Radiol); 1998; 10(5):313-7. PubMed ID: 9848332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]